OCULAR THERAPEUTIX, INC Share-based Payment Arrangement, Expense
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Payment Arrangement, Expense of $14.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC share-based payment arrangement, expense for the quarter ending 2026-06-30 was $14.65M, a 51.36% increase year-over-year.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, expense for the quarter ending 2026-03-31 was $15.58M, a 49.02% increase year-over-year.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, expense for the quarter ending 2025-12-31 was $11.36M, a 57.83% increase year-over-year.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, expense for the quarter ending 2025-09-30 was $11.69M, a 76.04% increase year-over-year.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, expense for fiscal 2025 was $43.18M, a 30.43% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, expense for fiscal 2024 was $33.11M, a 85.74% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, expense for fiscal 2023 was $17.82M, a 5.08% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, expense for fiscal 2022 was $16.96M, a 13.26% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.65M 10-Q · filed 2026-08-03 | $30.23M 10-Q · filed 2026-08-03 | $41.59M derived: sum of 3 quarters · filed 2026-08-03 | $53.28M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $15.58M 10-Q · filed 2026-05-05 | $26.94M derived: sum of 2 quarters · filed 2026-05-05 | $38.63M derived: sum of 3 quarters · filed 2026-05-05 | $48.31M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $11.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $23.05M derived: sum of 2 quarters · filed 2026-02-05 | $32.73M derived: sum of 3 quarters · filed 2026-08-03 | $43.18M 10-K · filed 2026-02-05 |
| 2025-09-30 | $11.69M 10-Q · filed 2025-11-04 | $21.37M derived: sum of 2 quarters · filed 2026-08-03 | $31.82M 10-Q · filed 2025-11-04 | $39.02M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $9.68M 10-Q · filed 2026-08-03 | $20.13M 10-Q · filed 2026-08-03 | $27.33M derived: sum of 3 quarters · filed 2026-08-03 | $33.97M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $10.46M 10-Q · filed 2026-05-05 | $17.65M derived: sum of 2 quarters · filed 2026-05-05 | $24.29M derived: sum of 3 quarters · filed 2026-05-05 | $35.59M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $13.84M derived: sum of 2 quarters · filed 2026-02-05 | $25.13M derived: sum of 3 quarters · filed 2026-02-05 | $33.11M 10-K · filed 2026-02-05 |
| 2024-09-30 | $6.64M 10-Q · filed 2025-11-04 | $17.93M derived: sum of 2 quarters · filed 2025-11-04 | $25.91M 10-Q · filed 2025-11-04 | $30.24M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-06-30 | $11.29M 10-Q · filed 2025-08-05 | $19.27M 10-Q · filed 2025-08-05 | $23.60M derived: sum of 3 quarters · filed 2026-02-05 | $28.11M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-03-31 | $7.98M 10-Q · filed 2025-05-05 | $12.31M derived: sum of 2 quarters · filed 2026-02-05 | $16.82M derived: sum of 3 quarters · filed 2026-02-05 | $21.23M derived: sum of 4 quarters · filed 2026-02-05 |
| 2023-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $8.84M derived: sum of 2 quarters · filed 2026-02-05 | $13.25M derived: sum of 3 quarters · filed 2026-02-05 | $17.82M 10-K · filed 2026-02-05 |
| 2023-09-30 | $4.51M 10-Q · filed 2024-11-14 | $8.93M derived: sum of 2 quarters · filed 2024-11-14 | $13.50M 10-Q · filed 2024-11-14 | $17.73M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $4.41M 10-Q · filed 2024-08-07 | $8.98M 10-Q · filed 2024-08-07 | $13.22M derived: sum of 3 quarters · filed 2025-03-03 | $17.46M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $4.57M 10-Q · filed 2024-05-07 | $8.81M derived: sum of 2 quarters · filed 2025-03-03 | $13.05M derived: sum of 3 quarters · filed 2025-03-03 | $17.33M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $8.47M derived: sum of 2 quarters · filed 2025-03-03 | $12.76M derived: sum of 3 quarters · filed 2025-03-03 | $16.96M 10-K · filed 2025-03-03 |
| 2022-09-30 | $4.24M 10-Q · filed 2023-11-07 | $8.52M derived: sum of 2 quarters · filed 2023-11-07 | $12.73M 10-Q · filed 2023-11-07 | $16.57M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $4.28M 10-Q · filed 2023-08-07 | $8.49M 10-Q · filed 2023-08-07 | $12.33M derived: sum of 3 quarters · filed 2024-03-11 | $16.09M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $4.21M 10-Q · filed 2023-05-08 | $8.05M derived: sum of 2 quarters · filed 2024-03-11 | $11.81M derived: sum of 3 quarters · filed 2024-03-11 | $16.10M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $7.60M derived: sum of 2 quarters · filed 2024-03-11 | $11.89M derived: sum of 3 quarters · filed 2024-03-11 | $14.98M 10-K · filed 2024-03-11 |
| 2021-09-30 | $3.76M 10-Q · filed 2022-11-07 | $8.05M derived: sum of 2 quarters · filed 2022-11-07 | $11.14M 10-Q · filed 2022-11-07 | $13.24M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $4.29M 10-Q · filed 2022-08-08 | $7.38M 10-Q · filed 2022-08-08 | $9.48M derived: sum of 3 quarters · filed 2023-03-06 | $11.42M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $3.09M 10-Q · filed 2022-05-09 | $5.19M derived: sum of 2 quarters · filed 2023-03-06 | $7.13M derived: sum of 3 quarters · filed 2023-03-06 | $8.95M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $4.04M derived: sum of 2 quarters · filed 2023-03-06 | $5.87M derived: sum of 3 quarters · filed 2023-03-06 | $7.53M 10-K · filed 2023-03-06 |
| 2020-09-30 | $1.94M 10-Q · filed 2021-11-08 | $3.76M derived: sum of 2 quarters · filed 2021-11-08 | $5.43M 10-Q · filed 2021-11-08 | $7.38M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.83M 10-Q · filed 2021-08-09 | $3.49M 10-Q · filed 2021-08-09 | $5.44M derived: sum of 3 quarters · filed 2022-02-28 | $8.61M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.67M 10-Q · filed 2021-05-05 | $3.62M derived: sum of 2 quarters · filed 2022-02-28 | $6.79M derived: sum of 3 quarters · filed 2022-02-28 | $8.48M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $5.12M derived: sum of 2 quarters · filed 2022-02-28 | $6.82M derived: sum of 3 quarters · filed 2022-02-28 | $8.76M 10-K · filed 2022-02-28 |
| 2019-09-30 | $3.17M 10-Q · filed 2020-11-05 | $4.86M derived: sum of 2 quarters · filed 2020-11-05 | $6.81M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.70M 10-Q · filed 2020-08-07 | $3.64M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $1.94M 10-Q · filed 2020-05-08 | |||
| 2018-09-30 | $1.87M 10-Q · filed 2019-11-12 | $3.70M derived: sum of 2 quarters · filed 2019-11-12 | $5.53M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $1.83M 10-Q · filed 2019-08-07 | $3.66M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $1.83M 10-Q · filed 2019-05-10 | |||
| 2017-09-30 | $1.75M 10-Q · filed 2018-11-07 | $3.51M derived: sum of 2 quarters · filed 2018-11-07 | $5.21M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $1.76M 10-Q · filed 2018-08-07 | $3.46M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $1.71M 10-Q · filed 2018-05-08 | |||
| 2016-09-30 | $1.37M 10-Q · filed 2017-11-07 | $2.88M derived: sum of 2 quarters · filed 2017-11-07 | $4.23M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $1.51M 10-Q · filed 2017-08-08 | $2.86M 10-Q · filed 2017-08-08 | ||
| 2014-12-31 | $977.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-20 | $1.58M derived: sum of 2 quarters · filed 2015-03-20 | $2.14M derived: sum of 3 quarters · filed 2015-03-20 | $2.64M 10-K · filed 2015-03-20 |
| 2014-09-30 | $607.00K 10-Q · filed 2014-11-12 | $1.16M derived: sum of 2 quarters · filed 2014-11-12 | $1.67M 10-Q · filed 2014-11-12 | $1.79M derived: sum of 4 quarters · filed 2015-03-20 |
| 2014-06-30 | $557.00K 10-Q · filed 2014-08-29 | $1.06M 10-Q · filed 2014-08-29 | $1.19M derived: sum of 3 quarters · filed 2015-03-20 | $1.31M derived: sum of 4 quarters · filed 2015-03-20 |
| 2014-03-31 | $503.00K derived: 10-K 12 month − 3 quarters · filed 2015-03-20 | $628.00K derived: sum of 2 quarters · filed 2015-03-20 | $749.00K derived: sum of 3 quarters · filed 2015-03-20 | $870.00K derived: sum of 4 quarters · filed 2015-03-20 |
| 2013-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-20 | $246.00K derived: sum of 2 quarters · filed 2015-03-20 | $367.00K derived: sum of 3 quarters · filed 2015-03-20 | $476.00K 10-K · filed 2015-03-20 |
| 2013-09-30 | $121.00K 10-Q · filed 2014-11-12 | $242.00K derived: sum of 2 quarters · filed 2014-11-12 | $351.00K 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $121.00K 10-Q · filed 2014-08-29 | $230.00K 10-Q · filed 2014-08-29 | ||
| 2012-12-31 | $243.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |